ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
0.00%
US Dollar vs MXN
18.23585
0.60%
Brent Oil
84.645
0.55%
Bitcoin
61,398.22
-0.67%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Salarius Pharmaceuticals Inc (SLRX)

  7. Salarius Pharmaceuticals Inc (SLRX) Noticias

SLRX

Salarius Pharmaceuticals (SLRX)

Salarius Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SLRX
FechaHoraFuenteTítuloSímboloCompañía
17/06/202407:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
17/06/202407:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
17/06/202407:00GlobeNewswire Inc.Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202407:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:SLRXSalarius Pharmaceuticals Inc
13/05/202415:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
22/03/202415:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202415:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202407:00GlobeNewswire Inc.Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesNASDAQ:SLRXSalarius Pharmaceuticals Inc
16/01/202407:00GlobeNewswire Inc.Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersNASDAQ:SLRXSalarius Pharmaceuticals Inc
03/01/202407:30GlobeNewswire Inc.Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNASDAQ:SLRXSalarius Pharmaceuticals Inc
07/11/202307:30GlobeNewswire Inc.Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramNASDAQ:SLRXSalarius Pharmaceuticals Inc
27/10/202314:57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:SLRXSalarius Pharmaceuticals Inc
10/08/202315:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
08/08/202315:05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its ResourcesNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/07/202307:30GlobeNewswire Inc.Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202307:00GlobeNewswire Inc.Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressNASDAQ:SLRXSalarius Pharmaceuticals Inc
08/06/202305:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SLRXSalarius Pharmaceuticals Inc
07/06/202306:28Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/06/202316:02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
26/05/202316:03Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
16/05/202315:34Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLRXSalarius Pharmaceuticals Inc
16/05/202315:05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/05/202307:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/05/202307:00GlobeNewswire Inc.Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
09/05/202307:00GlobeNewswire Inc.FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing SarcomaNASDAQ:SLRXSalarius Pharmaceuticals Inc
01/05/202307:30GlobeNewswire Inc.Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/05/202307:05Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/05/202307:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
20/04/202307:30GlobeNewswire Inc.Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
04/04/202315:02GlobeNewswire Inc.Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational ConferenceNASDAQ:SLRXSalarius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SLRX

Su Consulta Reciente

NYSE
JPM
JP Morgan Chase
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
AMEX
XLF
Financial Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
RHHBY
Roche (QX)
FX
EURUSD
Euro vs US Dollar
COIN
BTCUSD
Bitcoin
NASDAQ
MSFT
Microsoft
FX
EURMXN
Euro vs MXN
NASDAQ
GOOGL
Alphabet
CCOM
OILBRENT
Brent Oil
COIN
SOLUSD
Solana
NYSE
XOM
Exxon Mobil
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados